01 August 2023: Database Analysis
Impact of Pre-Transplant Parathyroidectomy on Graft Survival: A Comparative Study of Renal Transplant Patients (2005–2015)
Ming-Hsien Tsai 12ADEF* , Mingchih Chen 34ABD* , Hung-Hsiang Liou 5AD , Tian-Shyug Lee 34B , Yen-Chun Huang 34C , Pei-Yang Liu 6F , Yu-Wei Fang 12AEFG*DOI: 10.12659/MSM.940959
Med Sci Monit 2023; 29:e940959
Supplementary Table 3 Ranking of feature selection on graft failure in the patients receiving kidney translation.
| LGR | RF | KNN | XGB | Average | ||
|---|---|---|---|---|---|---|
| Parathyroidectomy | 13 | 13 | 20 | 7 | 13.25 | |
| Sex | 5 | 8 | 9 | 0 | 5.5 | |
| Age | 0 | 21 | 5 | 17 | 10.75 | |
| KT with complication | 23 | 18 | 24 | 19 | 21 | |
| Atrial fibrillation | 22 | 16 | 19 | 13 | 17.5 | |
| Hypertension | 8 | 11 | 0 | 6 | 6.25 | |
| Hyperuricemia | 3 | 3 | 6 | 0 | 3 | |
| Hyperlipidemia | 14 | 6 | 12 | 0 | 8 | |
| Myocardial infarct | 18 | 12 | 14 | 11 | 13.75 | |
| Liver cirrhosis | 24 | 19 | 18 | 18 | 19.75 | |
| Diabetes | 15 | 7 | 0 | 0 | 5.5 | |
| COPD | 11 | 10 | 15 | 0 | 9 | |
| Stroke | 21 | 14 | 21 | 8 | 16 | |
| PVD | 25 | 17 | 23 | 16 | 20.25 | |
| CHF | 17 | 15 | 22 | 10 | 16 | |
| Gout | 6 | 9 | 0 | 3 | 4.5 | |
| CCI | 19 | 20 | 7 | 14 | 15 | |
| Dialysis modality | HD | 2 | 0 | 16 | 15 | 8.25 |
| PD | 0 | 0 | 17 | 0 | 4.25 | |
| Lipid lowering agents | 0 | 0 | 10 | 2 | 3 | |
| ACEI_ARB | 7 | 0 | 11 | 0 | 4.5 | |
| β-blockers | 0 | 1 | 8 | 0 | 2.25 | |
| Insulin | 16 | 0 | 0 | 9 | 6.25 | |
| Anti-coagulants | 20 | 2 | 13 | 12 | 11.75 | |
| Anti gout | 1 | 0 | 1 | 0 | 0.5 | |
| Benzodiazepine | 9 | 4 | 3 | 5 | 5.25 | |
| CCB | 10 | 5 | 0 | 4 | 4.75 | |
| Diuretics | 12 | 0 | 4 | 0 | 4 | |
| OHA | 4 | 0 | 2 | 1 | 1.75 | |
| LGR – logistic regression; RF – random forest; KNN – k nearest neighbor; XGB – eXtreme Gradient Boosting. KT – kidney transplantation; COPD – chronic obstructive pulmonary; PVD – peripheral vascular disease; CHF – congestive heart failure; CCI – Charlson comorbidity index; HD – hemodialysis; PD – peritoneal dialysis; ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor blocker; CCB – calcium channel blocker; OHA – oral hypoglycemic agent. | ||||||